Despite advances in PCa imaging with magnetic resonance imaging (MRI) and prostate-specific membrane antigen (PSMA) positron emission tomography (PET), histopathologic verification remains the gold standard for establishing the diagnosis of PCa [3, 4]. This evidence concerns the gene FOLH1 and posterior cortical atrophy.